Preomics was founded in 2016 by Garwin Pichler and Nils A. Kulak as a spin-out company from the laboratory of proteomics researcher Professor Matthias Mann at the Max Planck Institute of Biochemistry in Martinsried. Startup supports pharmaceutical and clinical research with automation solutions and consumables for the homogenization, enrichment and proteomic sample preparation of biopsy, tissue, cell line and plasma samples. Garwin Pichler, co-founder and CEO of Preomics, says:
"We are pleased to increase our investments in R&D, marketing, and sales and to have Bruker as a collaboration partner and lead investor. Bruker shares our vision of making advanced technologies for proteomic analysis available to everyone and will accelerate our growth through this funding. Our existing and future customers and partners will benefit from the investments in Preomics and the synergies in proteomics solutions to expand our product offering and global presence."
The second co-founder and managing director Nils A. Kulak says:
"We see a promising future for Preomics' research, development, and commercialization activities, which will be accelerated by the Series B funding and Bruker as a partner. Our novel Beatbox technology is seamlessly compatible with Preomics' proteomics sample preparation technologies and, in combination with the TimsTOF Pro, offers complete workflows for processing large tissue biobanks. Our goal is to develop complete, user-friendly, and automated Beatbox-based workflows for any throughput, thus providing solutions for highly efficient proteomic analysis."
“Preomics is a leading proteomics company”
The investment represents a successful exit for several early-stage investors: High-Tech Gründerfonds and Thinkhealth Ventures, as well as several business angels, successfully sold their Preomics shares to Bruker in a parallel secondary transaction. The US company is now the majority investor in the Munich-based company. Financial details of the secondary transactions were not disclosed.
Bernd Goergen, partner at High-Tech Gründerfonds, says:
"That our time as a seed investor in Preomics is coming to an end after just five years is a testament to the fantastic performance of both the management and the highly innovative technology. Many thanks to Garwin and Nils for allowing us to be a part of your journey. The merger with your partner Bruker Inc. now paves the way to setting gold standards in protein preparation and will thus make proteomic analysis easier and more reliable than ever."
Frank H. Laukien, President and CEO of Bruker Corporation, says:
"We are very pleased to invest in Preomics, a leading company in sample preparation, automation, and consumables for proteomics, with this Series B financing. By acquiring a majority stake in Preomics, Bruker is expanding its proteomics vision to include Preomics' unique sample preparation technologies and complete, automated, robust, and reproducible workflows for translational biomarker and biopharma proteomics research."
